Traditional single-cell analysis methodologies, despite their immense contributions, often restrict researchers to a one-time examination of a cell, creating a barrier to understanding dynamic cellular changes and responses to external stimuli. This new technology leverages microscopic, semi-permeable capsules—each encapsulating a single cell—allowing sequential and multifaceted analyses while preserving the cellular contents intact. This breakthrough holds transformative potential for biological sciences, providing unprecedented insights into cellular diversity and disease progression.

The essence of the technology lies in the design of the semi-permeable capsules, consisting of a liquid core enveloped by a delicate yet robust porous membrane. This membrane is uniquely engineered to permit the passage of small molecules like enzymes, reagents, and other chemical agents, while selectively retaining larger biomolecules such as DNA and RNA within the capsule. This selective permeability ensures that the cell’s genetic material remains isolated and protected, facilitating multiple rounds of molecular analysis without contamination or sample loss.

By integrating this capsule technology with microfluidics—a technique that manipulates minute volumes of liquids with extraordinary precision—the researchers have crafted a platform capable of processing hundreds of thousands of individual cells simultaneously. The methodology retains the speed and scalability advantages of microfluidics but overcomes the key limitations of droplet-based systems commonly used in single-cell research.

One of the most important features of this technology is its compatibility with advanced molecular biology workflows. Unlike conventional methods, which often necessitate sacrificing the cell after a single analysis, these capsules allow stepwise experimental protocols to be performed sequentially on the very same cell. This capability opens avenues for sophisticated analyses such as performing sequential enzymatic reactions or chemical labeling, shedding new light on cellular processes as they unfold in real-time.

Crucially, the researchers demonstrated that cells can be maintained alive inside the capsules for extended durations, an achievement that enables longitudinal studies of cellular behaviors and responses. Alternatively, cells can also be deliberately lysed within the capsule environment to extract nucleic acids for high-resolution genetic analyses. This dual functionality enhances research flexibility, allowing scientists to explore diverse biological questions ranging from cell viability to comprehensive genomic sequencing.

An additional innovation introduced in this study is a novel RNA sequencing approach specifically tailored to work with the capsule technology. This method greatly improves the detection and characterization of fragile or rare cell populations—cell types that are typically lost or underrepresented in traditional single-cell sequencing techniques. By preserving these elusive cells, researchers are better equipped to understand their roles in health and disease, especially in heterogeneous tissues like tumors or immune cell populations.

The scalability, simplicity, and adaptability of this capsule-based platform signal its potential for broad adoption across biological and medical research disciplines. The capacity for repeated analyses on the same individual cells will undeniably accelerate discoveries in cell biology, immunology, and cancer research, among many others. For instance, monitoring how genetically identical cancer cells within the same tumor respond differently to chemotherapy drugs could inform more effective, personalized treatment strategies in oncology.

Looking forward, the implications of this technology extend well beyond laboratory research. Its precise, scalable nature could profoundly influence clinical diagnostics and therapeutic monitoring by enabling the early detection of critical cellular changes indicative of disease progression or treatment response. This technology could thus become instrumental in developing next-generation precision medicine frameworks tailored to individual patients’ cellular profiles.

Professor Mazutis emphasizes the importance of understanding intrinsic cell-to-cell variability to unravel disease mechanisms: “All cells are different, and discerning those differences is fundamental to advancing personalized medicine.” This statement encapsulates the core promise of the capsule technology—to expose and exploit the subtle molecular heterogeneity within cell populations that drives disease outcomes and therapeutic resistance.

Ultimately, this capsule-based single-cell analysis method represents a new paradigm in molecular biology research, combining innovative material science with microfluidic engineering to overcome prior technical obstacles. The capacity to execute high-throughput, multi-step molecular assays on isolated, live cells paves the way for a deeper and more nuanced understanding of biology at the most fundamental unit of life.

As the scientific community embraces this breakthrough, ongoing developmental efforts will likely enhance capsule designs and expand their integration with diverse omics technologies, including proteomics and metabolomics. This convergence promises to deliver an all-encompassing toolkit to explore cellular complexity with unparalleled accuracy and depth.

This work not only illustrates a remarkable technical advance but also underscores the synergy between interdisciplinary approaches—combining bioengineering, molecular biology, and computational methods—to push the frontiers of science. The new capsule-based platform sets an exciting precedent, heralding a future where the secrets of single cells can be decoded with unprecedented clarity and speed, ultimately catalyzing transformative impacts in biomedical research and healthcare.

Subject of Research: Cells
Article Title: High-throughput single cell omics using semipermeable capsules
News Publication Date: 18-Dec-2025
Web References: DOI: 10.1126/science.ady7227
Image Credits: Photo by Katažyna Samaitė
Keywords: Cell biology; Single cell sequencing; DNA sequencing; Biotechnology; Molecular biology

For decades, the scientific community has recognized hereditary patterns in diseases, an observation tracing back to Hippocrates. Nonetheless, the molecular mechanisms underlying these genetic correlations remained elusive, largely due to technological barriers in capturing the complex relationship between genomic variation and cellular function at a single-cell scale. Traditional single-cell sequencing technologies primarily interrogated either DNA or RNA, rarely both in tandem, and often focused on coding regions where expressed genes reside. This approach, while illuminating certain aspects of gene expression, overlooked the vast expanse of non-coding DNA—the regulatory landscapes where over 95% of disease-associated variants lie.

The SDR-seq platform pioneers a methodological leap by enabling simultaneous reading of genomic DNA and corresponding RNA transcripts in thousands of individual cells simultaneously. Utilizing sophisticated oil-water emulsion droplet microfluidics, each droplet encapsulates a single cell, ensuring that DNA and RNA information remains linked to its cellular origin throughout the processing pipeline. This design exponentially increases throughput and fidelity compared to prior methods, which suffered from limited cell numbers, sensitivity constraints, and technical complexity that impeded broad applicability.

One of the most significant innovations facilitated by SDR-seq is its capacity to detect variants across the entire genome, irrespective of whether they reside within coding exons or within the vast regulatory non-coding expanses. These non-coding regions contain crucial elements like enhancers, silencers, and insulators that orchestrate gene expression patterns fundamental to cellular identity and disease states. Identifying functional consequences of variants in these sections has long been a formidable challenge for genomics researchers, given the paucity of tools capable of capturing both genotype and phenotype from a single cell at sufficient scale.

Dominik Lindenhofer, lead author and postdoctoral scientist at EMBL’s Steinmetz Group, highlights that SDR-seq overcomes these hurdles by “yielding single-cell numbers that enable analysis of complex samples,” thereby providing an unprecedented window into genomic variance that influences cell behavior. Unlike prior approaches limited to expressed (coding) regions, SDR-seq deciphers DNA variants anywhere in the genome, including silent regions, offering a holistic perspective on genomic architecture and its functional outcomes.

The technology’s innovative core further leverages a complex DNA barcoding system that labels both DNA and RNA molecules within each droplet, enabling precise mapping of molecular reads back to individual cells. This system was computationally optimized by Oliver Stegle’s group at EMBL, who developed customized algorithms to decode the intricate barcodes and manage downstream data integration. Their bioinformatics pipeline not only supports SDR-seq but holds promise for diverse applications demanding multiomic single-cell resolution.

Collaborations were instrumental to the refinement and validation of SDR-seq. Teams from Stanford University School of Medicine and Heidelberg University Hospital supplied primary B-cell lymphoma samples characterized by extensive genomic variability. These samples served as rigorous test beds to assess SDR-seq’s sensitivity and its ability to reveal variant-driven alterations in gene expression. The results illuminated compelling connections: lymphoma cells with higher variant burdens exhibited more aggressive transcriptional profiles underlying malignancy, suggesting SDR-seq can unravel mechanistic insights into cancer progression at a level hitherto unattainable.

Furthermore, Lindenhofer explained that the tool elucidates allelic dosage by determining whether variants are present on one or both gene copies within a cell. This granularity allows researchers to quantify the effect of heterozygous versus homozygous mutations on gene expression phenotypes, bridging a critical gap between genotype and cellular function. Such detailed single-cell resolution promises to shed light on disease heterogeneity, cellular plasticity, and therapy resistance mechanisms.

Beyond cancer biology, the implications of SDR-seq extend across biomedical research. Non-coding variant exploration enabled by this technology opens up investigative routes into complex disorders like congenital heart disease, autism, and schizophrenia, where regulatory genetic components have remained enigmatic. By decoding how these variants functionally modulate gene networks within their native genomic contexts, scientists can better understand disease etiology and identify novel molecular targets for intervention.

Lars Steinmetz, senior author and group leader at EMBL as well as professor at Stanford, emphasizes the transformative potential of SDR-seq. He notes that by “linking variants to disease,” the technology “opens up a wide range of biology that we can now discover.” This capability is poised to fundamentally shift how genetic information is used to inform diagnostics, prognostics, and treatment strategies, promising improved precision medicine approaches for a myriad of conditions.

The seamless integration of microfluidic engineering, molecular biology, and computational innovation embodied in SDR-seq exemplifies the power of interdisciplinary collaboration in modern genomics. It sets a new standard for scale, precision, and sensitivity in single-cell multiomic profiling, making it an indispensable tool for scientists aiming to decode the complex interplay between genome and transcriptome within individual cells.

As SDR-seq technology continues to mature, it is anticipated to catalyze new research frontiers in developmental biology, immunology, oncology, and beyond. Its ability to directly couple genomic identity with transcriptional output in thousands of cells simultaneously paves the way for comprehensive cellular atlases that capture the nuances of health and disease at single-cell resolution.

The scientific community eagerly awaits broader deployment of SDR-seq, alongside further methodological refinements and computational advancements, which collectively will accelerate discoveries into the functional genomic variants shaping human biology. This powerful new lens on the genome promises not only deeper understanding, but also tangible improvements in diagnostics and therapeutic intervention for complex diseases, marking a new era in precision genomics.

Subject of Research: Cells

Article Title: Functional phenotyping of genomic variants using multiomic scDNA-scRNA-seq

News Publication Date: 1-Sep-2025

Web References: 10.1038/s41592-025-02805-0

Image Credits: Daniela Velasco/EMBL

Keywords: Molecular biology, Molecular genetics

However, traditional fluorescence flow cytometry is not without its drawbacks. The necessity for fluorescent labels introduces complexity, cost, and time delays, often limiting throughput and reproducibility. Addressing these challenges, impedance flow cytometry has emerged as an innovative substitute that replaces optical detection with electrical measurements. By using electrodes strategically positioned alongside the microfluidic channel, impedance flow cytometers measure changes in electrical impedance as particles pass through the sensing region, circumventing the need for fluorescent dyes altogether.

Despite the promise of this label-free technique, impedance flow cytometry has been hampered by intrinsic limitations, most notably in sensitivity and signal consistency. A significant factor is the variability in distance between the cells and the electrodes, which fluctuates according to microchannel height and the size of the passing cells. This inconsistency creates challenges in reliably detecting small variations in impedance, thus limiting the technology’s application in environments demanding high accuracy.

Seeking to bridge this gap, a research team led by Associate Professor Yalikun Yaxiaer from the Nara Institute of Science and Technology (NAIST) in Japan engineered a groundbreaking platform that dramatically elevates the performance of impedance flow cytometry. Their work, published in the renowned journal Lab on a Chip, presents a low-cost yet highly effective system that dynamically adapts the microchannel’s height in real-time based on the dimensions of the particles passing through.

The crux of their innovation lies in a simple yet elegant mechanical modification: the integration of a precision-controlled metal probe attached to an XYZ translation stage. This device allows meticulous three-dimensional positioning, and by manipulating the vertical axis, the probe gently presses against the top wall of the microfluidic channel, which initially measures about 30 micrometers in height. The mechanical compression thereby reduces the channel height dynamically, bringing cells into closer proximity with the sensing electrodes.

By enabling this adaptive channel height adjustment, the research team successfully amplified the impedance signal by approximately three times after reducing the channel height by one-third. Alongside this amplification, they halved the variability of the electrical signal. This combination of heightened sensitivity and enhanced signal stability empowers the accurate discrimination of multiple cell types differing in size and electrical properties—an achievement that addresses a major bottleneck in current impedance cytometry.

To further optimize the system’s reliability, the researchers deployed a camera coupled with an advanced object-detection algorithm, transforming a common hurdle in microfluidic technologies—clogging—into a functional asset. Typically, clogging, the unwanted aggregation of particles that obstructs fluid flow, presents a critical risk, often forcing interruptions and rewrites of experimental protocols. Instead, Dr. Yaxiaer and colleagues leveraged controlled, slight channel constrictions to maximize sensitivity, while the algorithm detects impending clogging events in real-time and signals the immediate relaxation of channel compression, thus preventing full blockage.

This innovative strategy essentially creates a “smart” microfluidic channel capable of adaptive self-regulation, actively responding to changing conditions within the flow to maintain optimal performance. By harnessing this intelligent clogging-release mechanism, the system ensures long-term operational stability and greatly reduces manual intervention, a typically labor-intensive component of flow cytometry workflows.

The implications of this advancement extend far beyond laboratory curiosities. A universal, adaptive impedance flow cytometry platform that is simple to operate, highly sensitive, and resistant to clogging holds significant potential for clinical diagnostics. For instance, point-of-care testing—crucial in resource-limited settings—could be revolutionized through deployment of such devices, allowing rapid, reliable blood analyses or pathogen detection without the infrastructure-heavy needs of conventional cytometry.

Moreover, the platform offers exciting prospects for pharmaceutical development and drug testing. High-throughput, precise single-cell analysis can accelerate screening processes, enabling researchers to monitor cellular responses to candidate molecules with greater fidelity and less overhead linked to sample preparation or reagent use.

The team’s interdisciplinary approach, integrating microfluidics, electrical engineering, and artificial intelligence, exemplifies the kind of collaborative innovation essential to push biomedical technologies into new regimes of performance. Their system’s elegance lies not only in its mechanical simplicity but also in the seamless fusion of hardware control and software intelligence, enabling fine-tuned real-time adjustments rarely seen in flow cytometry platforms.

Associate Professor Yaxiaer emphasizes that this platform is poised to become a cornerstone for standardizing impedance flow cytometry methods worldwide. By providing a universal method adaptable to diverse cell types and experimental conditions, the technology addresses a long-standing need for consistency and reproducibility across laboratories and clinical settings. It marks a significant stride towards making impedance flow cytometry accessible, reliable, and broadly applicable.

Looking ahead, collaborations with medical institutions and industry stakeholders are anticipated to translate this promising research into commercial diagnostic devices. Integrating such an adaptive system with clinical workflows could open new frontiers in rapid disease detection, immunophenotyping, and personalized medicine—all while cutting costs and reducing dependence on fluorescent labeling reagents.

In sum, the NAIST-led study charts an inspiring course toward the next generation of flow cytometry—one defined by adaptability, affordability, and robustness. By smartly tailoring the physical microenvironment on-the-fly and marrying this with real-time image analysis, the team has set a new benchmark for electrical single-cell analysis technologies. As this innovation gains traction, it is likely to galvanize future explications of cellular heterogeneity and accelerate breakthroughs that harness the power of cells to unlock mysteries of health and disease.

Subject of Research:
Not applicable

Article Title:
A long-term universal impedance flow cytometry platform empowered by adaptive channel height and real-time clogging-release strategy

News Publication Date:
26-Aug-2025

Web References:
https://doi.org/10.1039/D5LC00673B

References:
Julian, T., Tang, T., Tanga, N., Yang, Y., Hosokawa, Y., & Yaxiaer, Y. (2025). A long-term universal impedance flow cytometry platform empowered by adaptive channel height and real-time clogging-release strategy. Lab on a Chip. https://doi.org/10.1039/D5LC00673B

Keywords:
Life sciences, Cytometry, Flow cytometry, Biophysics, Biomechanics, Bioelectricity, Cell density, Cell size, Cell structure, Cells

Now, a breakthrough from an interdisciplinary team at the Massachusetts Institute of Technology (MIT) promises to revolutionize how researchers and clinicians assess cellular states by enabling rapid, high-throughput single-cell density measurements. Leveraging cutting-edge microfluidic and optical technologies, this new technique can analyze up to 30,000 individual cells within just one hour, offering an unprecedented window into the dynamic physical properties that govern immune responses and cancer drug sensitivities.

Precise quantification of cell density offers an indirect but powerful snapshot of the molecular crowding within a cell’s cytoplasm and nucleus. Changes in density can reflect fluctuations in the abundance of lipids, proteins, nucleic acids, and, critically, water content. These shifts correlate with functional transitions, such as T cell activation or tumor cell susceptibility to chemotherapeutic agents. By carefully measuring these physical parameters with exceptional sensitivity and scale, the MIT team has unlocked the potential for new diagnostic and predictive biomarkers that complement traditional molecular analyses.

The foundation of this method builds on seminal work from MIT’s Manalis laboratory, which over the last two decades has pioneered the suspended microchannel resonator (SMR) technology. This microfluidic device utilizes a cantilever with an embedded microchannel that vibrates at specific frequencies. As a single cell flows through, the change in vibration frequency corresponds directly to its buoyant mass—a measure influenced by the cell’s mass and the density of the surrounding fluid. The frequency shift allows researchers to calculate the cell’s mass with extraordinary precision.

Previous iterations of this technology required cells to pass through the resonator multiple times suspended in fluids of varying densities to derive cell volume, and thereby calculate density. Although successful, this approach significantly constrained throughput, limiting its application to roughly a few hundred cells per experiment due to the complexity and temporal demands of fluid swapping.

Addressing these constraints, the MIT researchers have ingeniously integrated the SMR device with a fluorescence microscopy system that accurately measures cell volume in real time. By staining the suspension fluid with a fluorescent dye impermeable to cell membranes, the passage of each cell creates a transient dip in fluorescence intensity that corresponds to the cell’s volume. This volumetric information, combined with the subsequent resonator-based mass measurement, enables rapid calculation of cell density as the cells flow through the device in a continuous, one-pass manner. This streamlined methodology dramatically increases throughput without compromising measurement accuracy or sensitivity.

The implications of this technological advance extend deeply into immunology. Using this system, the team investigated the density dynamics of T cells as they transition from a resting quiescent state to an active, proliferative one triggered by antigenic stimulation. Remarkably, they observed a decrease in average cell density from approximately 1.08 grams per milliliter to 1.06 grams per milliliter within the first day post-activation. This reduction indicates an influx of water into the cells, causing them to swell and become less crowded with biomolecules. These findings provide compelling evidence that changes in cellular water content—and thus density—serve as meaningful biomarkers of immune cell fitness and functionality.

This functional relevance of density measurements holds clinical promise. The startup company Travera, co-founded by Professor Scott Manalis, has leveraged SMR technologies to predict the responsiveness of individual patients’ T cells to immunomodulatory drugs aimed at eliciting potent anti-tumor effects. Preliminary investigations reveal that combining cell mass and density measurements markedly enhances the predictive accuracy of immune cell competency, signaling a new path for personalized immunotherapy monitoring.

Beyond immune cells, the utility of this approach is underscored in oncology research. The MIT team applied their platform to pancreatic cancer cell lines exposed to chemotherapeutic agents with distinct efficacy profiles. They demonstrated that density changes following treatment were strongly indicative of cellular responses—distinguishing drug-susceptible cells undergoing apoptosis from resistant populations. These observations suggest that cell density measurements facilitate rapid, non-invasive predictions of tumor drug sensitivity, potentially informing precision oncology decisions within days.

Looking forward, Professor Manalis’ laboratory is expanding applications of these mass-density markers to optimize the production of complex biologics such as therapeutic antibodies. By monitoring the fitness and metabolic state of producer cells, this technique may enable real-time quality control and process refinement, advancing biomanufacturing efficiency and therapeutic yield.

The convergence of microfluidics, resonant sensing, and fluorescence microscopy manifests in a remarkable fusion of physical and biological insight. The ability to measure subtle, rapid changes in single-cell density at high throughput bridges a longstanding gap between physical biophysics and practical biomedical applications. It is a compelling example of how engineering innovations can uncover new dimensions of cell biology, with potential impacts ranging from immunotherapy to drug development and beyond.

Funded through support by the Paul G. Allen Frontiers Group, the Virginia and Daniel K. Ludwig Fund for Cancer Research, MIT’s Center for Precision Cancer Medicine, the Stand up to Cancer Convergence Program, Bristol Myers Squibb, and the National Cancer Institute’s Koch Institute Support Grant, this multidisciplinary effort highlights collaborative investment in technologies poised to transform biomedical research landscapes.

The publication of this study, led by MIT research scientist Weida (Richard) Wu and senior author Professor Scott Manalis, in the prestigious journal Nature Biomedical Engineering, marks a significant milestone in cell measurement science. It offers the scientific community a robust new tool to rapidly profile and predict cellular states, with broad ramifications for diagnostics, therapeutics, and industrial biotechnology.

As the field moves forward, the integration of high-throughput physical measurements promises not only to complement genomic and proteomic profiling but also to reveal new layers of cellular heterogeneity and function. By quantifying biophysical properties that have hitherto been difficult to access at scale, researchers are gaining a richer, more nuanced understanding of cell biology—one that could fundamentally reshape disease treatment paradigms and personalized medicine strategies worldwide.

Subject of Research: Cell density measurement and its application to immune cell activation and cancer drug response.

Article Title: High-throughput single-cell density measurements enable dynamic profiling of immune cell and drug response from patient samples

News Publication Date: 20-May-2025

Web References: 10.1038/s41551-025-01408-6

Keywords: Cancer, Cell density, Cell proliferation, Immune cells, Cancer cells, Cell biology, Diseases and disorders, Health and medicine

Tissue samples are notoriously complex, comprised of varied populations of cells intricately interwoven with distinct molecular compositions. Traditional biochemical techniques often obscure this complexity by averaging molecular data across numerous cells, blurring essential details critical for understanding pathological mechanisms. The Osaka team’s approach circumvents these limitations by enabling analyses at the single-cell level, revealing the molecular heterogeneity that underpins cellular function and dysfunction.

At the heart of this breakthrough lies t-SPESI, a technique that couples a finely controlled scanning probe with electrospray ionization to enable spatially resolved sampling of molecular species. Unlike conventional mass spectrometry imaging methods that often lack the spatial resolution to isolate subcellular regions, t-SPESI works by delicately tapping the probe onto targeted regions of a cell’s surface. This process extracts minute molecular samples with high spatial precision, which are then subjected to mass spectrometric analysis to identify and quantify the chemical constituents with accuracy.

A key innovation presented by the researchers is the development of a novel t-SPESI apparatus that integrates seamlessly with an inverted fluorescence microscope. This design advancement allows real-time visualization of the sampling process, providing unprecedented insight into how and where molecular data are collected. By observing the microscopic sample simultaneously in multiple imaging modes, researchers can correlate fluorescence-tagged molecular distributions with mass spectrometry data, creating a comprehensive multimodal portrait of cellular architecture and chemistry.

The multimodal nature of this system is particularly transformative. It can detect fluorescently labeled biomolecules, discern the topography of the cell surface, and map the molecular species inside the cell through mass spectrometric imaging. This rich dataset provides a three-dimensional window into cellular heterogeneity, revealing how chemical gradients, membrane structures, and metabolic activities vary within and between individual cells.

One of the initial demonstrations of this approach involved the visualization of lipid distributions within HeLa cells, a widely used human cell line in biomedical research. Lipids, crucial components of cellular membranes and signaling pathways, are known to exhibit diverse behaviors linked to metabolic health and disease processes. By mapping the intracellular localization of lipids, the researchers could directly observe variations in membrane composition and lipid metabolism at the single-cell level — insights that are often lost in bulk analyses.

The precision of this technology enabled distinctions between different cell types based on their unique lipid profiles and surface morphology. These findings herald a future where detailed molecular fingerprints of diseased versus healthy cells can be discerned within complex tissues, an advancement that bears significant implications for diagnostics and therapeutics. The ability to visualize such multidimensional molecular information offers a powerful tool for unraveling the molecular underpinnings of diseases such as cancer, neurodegeneration, and metabolic disorders.

The integration of mass spectrometry with fluorescence microscopy in the t-SPESI system also provides a pathway to link molecular distributions with cellular phenotypes, a vital step towards understanding the heterogeneity in cell populations. As diseases often arise from subtle changes in cellular composition and function, this technology could enable researchers to detect early molecular signs of pathology before morphological symptoms become apparent.

Beyond basic research, the implications for precision medicine are considerable. By enabling single-cell analysis in complex tissue samples, the technology may facilitate the identification of subpopulations of cells that respond differently to treatments, enabling more targeted and effective therapeutic interventions. Moreover, the detailed mapping of metabolic and signaling molecules within single cells could lead to the discovery of new biomarkers for disease progression and treatment response.

The method’s adaptability to various sample types and fluorescent labeling strategies also renders it a versatile platform for studying diverse biological questions. From tracking lipid metabolism in cancer cells to exploring neuronal signaling pathways, t-SPESI’s capacity to generate multidimensional molecular data sets a new standard for cellular imaging technologies.

Lead author Yoichi Otsuka emphasized the unit’s capability to observe the micro-sampling simultaneously, providing a unique window into the interactive molecular environment of cells. Equally, senior author Michisato Toyoda highlighted the system’s capacity to simultaneously visualize lipids, fluorescence signals, and topographic features, underlining its multifaceted analytical power.

In sum, this innovative merging of microscopy and mass spectrometry embodies a significant stride toward unraveling the complex molecular tapestry of cellular life. The resultant granular understanding of single-cell molecular landscapes promises to illuminate the mechanisms of disease with unprecedented clarity, fostering future breakthroughs in diagnostics, drug development, and therapeutic strategies. As the technology matures and becomes more widely adopted, its impact on precision medicine and biomedicine at large is poised to be profound.

Subject of Research: Cells
Article Title: Single-Cell Mass Spectrometry Imaging of Lipids in HeLa Cells via Tapping-Mode Scanning Probe Electrospray Ionization
News Publication Date: 14-May-2025
Web References: http://dx.doi.org/10.1038/s42004-025-01521-2
References: “Single-Cell Mass Spectrometry Imaging of Lipids in HeLa Cells via Tapping-Mode Scanning Probe Electrospray Ionization,” Communications Chemistry, DOI: 10.1038/s42004-025-01521-2
Image Credits: Yoichi Otsuka
Keywords: Electrospray ionization, Lipid metabolism, Lipids, Membrane lipids, Metabolic health, Single cell profiling, Single cells, Spectroscopy, Imaging analysis